INMUNE BIO INC (INMB) Stock News

USA - Nasdaq - NASDAQ:INMB - US45782T1051 - Common Stock

1.75 USD

-0.01 (-0.57%)

Last: 12/4/2025, 10:32:53 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

INMB Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: INmune Bio, Inc.

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

3 days ago - By: INmune Bio, Inc.

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

16 days ago - By: INmune Bio, Inc.

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

16 days ago - By: INmune Bio, Inc.

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

a month ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: Zacks Investment Research

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

a month ago - By: INmune Bio, Inc.

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

a month ago - By: INmune Bio, Inc.

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

a month ago - By: INmune Bio, Inc.

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

2 months ago - By: INmune Bio, Inc.

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

2 months ago - By: INmune Bio, Inc.

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

2 months ago - By: INmune Bio, Inc.

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

2 months ago - By: INmune Bio, Inc.

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

3 months ago - By: INmune Bio, Inc.

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

3 months ago - By: INmune Bio, Inc.

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

3 months ago - By: Zacks Investment Research

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4 months ago - By: The Motley Fool

INmune Bio (INMB) Q2 Loss Widens 110%

4 months ago - By: INmune Bio, Inc.

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

4 months ago - By: INmune Bio, Inc.

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

4 months ago - By: INmune Bio, Inc.

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

4 months ago - By: INmune Bio, Inc.

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

4 months ago - By: INmune Bio, Inc.

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

4 months ago - By: INmune Bio, Inc.

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

4 months ago - By: INmune Bio, Inc.

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

4 months ago - By: INmune Bio, Inc.

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

4 months ago - By: INmune Bio, Inc.

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

5 months ago - By: Yahoo Finance - Mentions: NVDA SPY QQQ META ...

Stock market today: S&P 500, Nasdaq jump to fresh records, capping stunning second-quarter comeback

5 months ago - By: INmune Bio, Inc.

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

5 months ago - By: INmune Bio, Inc.

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules